Literature DB >> 15961591

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.

Caroline L Trotter1, Nigel J Gay, W John Edmunds.   

Abstract

Much interest has surrounded the use of conjugate vaccines in recent years, with the development of vaccines against disease caused by Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae. These vaccines offer the potential for safe and effective disease control, but some questions remain, particularly regarding the duration and mechanisms of protection and the longer-term impact of vaccination on carriage. In this paper, the authors use data on immunization with serogroup C meningococcal conjugate vaccines in England and Wales to develop and apply a mathematical model to investigate the direct and indirect (herd immunity) effects of a conjugate vaccine program. A realistic, age-structured, dynamic model was developed and parameterized and was fitted to epidemiologic data from England and Wales. The effects of a range of vaccine strategies, including hypothetical scenarios, were investigated. The basic reproduction number was estimated to be 1.36. Catch-up vaccination targeting teenagers generated substantial herd immunity and was important in controlling disease rapidly. The results were sensitive to changes in the assumptions regarding the method of vaccine action, particularly duration of protection and efficacy of vaccination against carriage acquisition. This model can be used to help predict the potential impact of vaccine strategies both in the United Kingdom and elsewhere.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961591     DOI: 10.1093/aje/kwi160

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  53 in total

1.  Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles.

Authors:  N Bharti; H Broutin; R F Grais; M J Ferrari; A Djibo; A J Tatem; B T Grenfell
Journal:  Epidemiol Infect       Date:  2011-10-05       Impact factor: 2.451

2.  Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.

Authors:  J McVernon; M E Ramsay; A R McLean
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

3.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

4.  Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.

Authors:  David S Stephens
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

5.  Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes.

Authors:  Sarah Cobey; Marc Lipsitch
Journal:  Science       Date:  2012-03-01       Impact factor: 47.728

6.  Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria.

Authors:  Matthew J Ferrari; Florence Fermon; Fabienne Nackers; Augusto Llosa; Claire Magone; Rebecca F Grais
Journal:  Int Health       Date:  2014-09-05       Impact factor: 2.473

7.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

8.  Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

Authors:  A Khatami; A Peters; H Robinson; N Williams; A Thompson; H Findlow; A J Pollard; M D Snape
Journal:  Clin Vaccine Immunol       Date:  2011-10-28

9.  Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVacR).

Authors:  Prasad S Kulkarni; Suresh S Jadhav; F Marc LaForce
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

10.  Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Authors:  Alessia Melegaro; Yoon Hong Choi; Robert George; W John Edmunds; Elizabeth Miller; Nigel J Gay
Journal:  BMC Infect Dis       Date:  2010-04-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.